<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672278</url>
  </required_header>
  <id_info>
    <org_study_id>BS/CR/PC/01</org_study_id>
    <nct_id>NCT04672278</nct_id>
  </id_info>
  <brief_title>Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Safety, Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients With Mild to Moderate Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled, cross-over study.&#xD;
      Subjects who meet the inclusion/exclusion criteria will be randomly and alternatively&#xD;
      assigned to receive Shanzha fruit drink or placebo drink in the first 2 months or the last&#xD;
      two months of the 5 months study period. In between the first and second treatment period,&#xD;
      all patients will enter a Washout Period of 4 weeks and during which time patients should not&#xD;
      receive any of the study functional fruit drink.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the hypolipidemic effect of Shanzha Fruit drink in patients with hyperlipidemia</measure>
    <time_frame>5 months.</time_frame>
    <description>The lipid profile including total cholesterol, HDL cholesterol, LDL-cholesterol and triglycerides will be measured at the start and the end of the study and changes from the baseline to the end of the treatment will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of Shanzha Fruit drink in patients with hyperlipidemia by monitoring of liver function tests.</measure>
    <time_frame>5 months.</time_frame>
    <description>Alanine transaminase (ALT) levels as the main liver function test will be measured at the start and the end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the hypotensive effect of Shanzha Fruit Drink</measure>
    <time_frame>5 months.</time_frame>
    <description>The changes in the systolic and diastolic blood pressure from the baseline to the end of the treatment will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of Shanzha Fruit drink in patients with hyperlipidemia by recording any adverse events reported by the study subjects or noted by the investigator.</measure>
    <time_frame>5 months.</time_frame>
    <description>Any adverse events reported by the study subjects or noted by the investigator will be recorded at all the study visits after the initial study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Shanzha Fruit drink or placebo drink</intervention_name>
    <description>The dosage of Shanzha fruit drink or the placebo is 3 cans per day</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Total Cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l).&#xD;
&#xD;
               -  Mean plasma triglyceride &gt;= 4.5 mmol/l.&#xD;
&#xD;
               -  Diastolic blood pressure 95-100 mm Hg and/or Systolic blood pressure 130-150 mm&#xD;
                  Hg.&#xD;
&#xD;
               -  Be able to give written informed consent prior to study start and comply with&#xD;
                  study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Total Cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l).&#xD;
&#xD;
               -  Mean plasma triglyceride &lt; 4.5 mmol/l.&#xD;
&#xD;
               -  Diastolic blood pressure 95-100 mm Hg and/or Systolic blood pressure 130-150 mm&#xD;
                  Hg.&#xD;
&#xD;
               -  Be able to give written informed consent prior to study start and comply with&#xD;
                  study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Brian Tomlinson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

